S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:MGTX

MeiraGTx Stock Forecast, Price & News

$17.54
-0.98 (-5.29%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.32
$18.72
50-Day Range
$12.78
$21.50
52-Week Range
$11.60
$23.15
Volume
161,485 shs
Average Volume
190,395 shs
Market Capitalization
$779.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.53
30 days | 90 days | 365 days | Advanced Chart
Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.


MeiraGTx logo

About MeiraGTx

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Headlines

MeiraGTx (NASDAQ:MGTX) Issues Earnings Results
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGTX
Fax
N/A
Employees
219
Year Founded
N/A

Sales & Book Value

Annual Sales
$15.56 million
Book Value
$4.23 per share

Profitability

Net Income
$-57.99 million
Net Margins
-391.81%
Pretax Margin
-391.81%

Debt

Price-To-Earnings

Miscellaneous

Free Float
38,537,000
Market Cap
$779.65 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

158th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

25th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

Is MeiraGTx a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx
or view top-rated stocks.

How has MeiraGTx's stock been impacted by COVID-19?

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MGTX stock has increased by 24.4% and is now trading at $17.54.
View which stocks have been most impacted by COVID-19
.

Are investors shorting MeiraGTx?

MeiraGTx saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,250,000 shares, an increase of 23.8% from the October 31st total of 1,010,000 shares. Based on an average trading volume of 318,900 shares, the days-to-cover ratio is presently 3.9 days. Approximately 3.9% of the company's stock are sold short.
View MeiraGTx's Short Interest
.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for MeiraGTx
.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.08. The business had revenue of $6.95 million for the quarter, compared to the consensus estimate of $5 million. MeiraGTx had a negative net margin of 391.81% and a negative trailing twelve-month return on equity of 37.57%.
View MeiraGTx's earnings history
.

What price target have analysts set for MGTX?

3 analysts have issued 12 month price objectives for MeiraGTx's stock. Their forecasts range from $26.00 to $27.00. On average, they anticipate MeiraGTx's stock price to reach $26.50 in the next year. This suggests a possible upside of 51.1% from the stock's current price.
View analysts' price targets for MeiraGTx
or view top-rated stocks among Wall Street analysts.

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the following people:

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by a number of institutional and retail investors. Top institutional investors include Johnson & Johnson (6.52%), BlackRock Inc. (4.28%), 683 Capital Management LLC (2.97%), Prosight Management LP (0.66%), Geode Capital Management LLC (0.59%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Richard Giroux, Stuart Naylor and Thomas E Shenk.
View institutional ownership trends for MeiraGTx
.

Which institutional investors are selling MeiraGTx stock?

MGTX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Ensign Peak Advisors Inc, California State Teachers Retirement System, New York State Common Retirement Fund, Los Angeles Capital Management LLC, Geode Capital Management LLC, Morgan Stanley, and Citigroup Inc.. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes, Elizabeth A Cook, Richard Giroux, and Stuart Naylor.
View insider buying and selling activity for MeiraGTx
or view top insider-selling stocks.

Which institutional investors are buying MeiraGTx stock?

MGTX stock was bought by a variety of institutional investors in the last quarter, including Johnson & Johnson, Dimensional Fund Advisors LP, Martingale Asset Management L P, 683 Capital Management LLC, Prosight Management LP, SG Americas Securities LLC, Trexquant Investment LP, and Bank of New York Mellon Corp.
View insider buying and selling activity for MeiraGTx
or or view top insider-buying stocks.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $17.54.

How much money does MeiraGTx make?

MeiraGTx has a market capitalization of $779.65 million and generates $15.56 million in revenue each year. The company earns $-57.99 million in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does MeiraGTx have?

MeiraGTx employs 219 workers across the globe.

What is MeiraGTx's official website?

The official website for MeiraGTx is www.meiragtx.com.

Where are MeiraGTx's headquarters?

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company can be reached via phone at (646) 860-7985 or via email at [email protected].


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.